se of IgM enriched immunoglobulin in patients with severe bacterial infections in Intensive care
Phase 2
- Conditions
- Health Condition 1: A499- Bacterial infection, unspecified
- Registration Number
- CTRI/2018/10/015960
- Lead Sponsor
- IPGMER Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age >= 18 years
Diagnosis of severe bacterial infection
Ig M enriched immunoglobulin use
signed informed consent for data collection
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Documentation of Ig M enriched immunoglobulin use and definition of quality standards for Ig M enriched immunoglobulin use while addressing :1. Efficacy of Ig M enriched immunoglobulin use <br/ ><br> 2.Safety of Ig M enriched immunoglobulin use <br/ ><br>Timepoint: Upto 24 hours after last application
- Secondary Outcome Measures
Name Time Method 1. Comparison between APACHE II and SAPS II predicted mortality vs. observed hospital mortality <br/ ><br> 2.Difference in SOFA scores, baseline vs. posttreatment (24 h after last application) assessment. <br/ ><br>Timepoint: Upto 24hours after last application